Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $68,023.80 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Elaine Mary Shannon sold 3,978 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $68,023.80. Following the transaction, the insider directly owned 63,333 shares of the company’s stock, valued at $1,082,994.30. This trade represents a 5.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The stock’s 50-day simple moving average is $16.57 and its 200 day simple moving average is $17.14. The firm has a market capitalization of $56.53 billion, a PE ratio of 51.89 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion during the quarter. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 0.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on TAK shares. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 6.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after buying an additional 632 shares during the period. Franklin Resources Inc. grew its holdings in Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares during the last quarter. Abel Hall LLC grew its holdings in Takeda Pharmaceutical by 2.3% during the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after acquiring an additional 781 shares during the last quarter. Private Trust Co. NA increased its position in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the period. Finally, Checchi Capital Advisers LLC increased its position in Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after acquiring an additional 786 shares during the period. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.